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Abstract
Background: Bronchoalveolar lavage is a useful bronchoscopy technique. However, studies in “normal” children
populations are few. Furthermore, the anti-inflammatory effects of exogenous pulmonary surfactants on the
bronchoalveolar cellular components are limited.
Methods: Thirty children, aged 3 to 14 years, underwent diagnostic bronchoscopy and bronchoalveolar lavage.
Differential cytology, cytokine and chemokine measurements were performed on the fluid after exogenous
surfactant exposure. The aim of the study was to investigate the potential anti-inflammatory effects of exogenous
surfactants on the bronchoalveolar lavage fluid, specifically alveolar macrophages of healthy South African children.
Results: Alveolar macrophages were the predominant cellular population in normal children. Patients with inflammatory
pneumonopathies had significantly more neutrophils. Levels of inflammatory cytokines were significantly lower after
exogenous surfactant exposure. Moreover, IL-10 and IL-12 cytokine secretion increased after exogenous surfactant
exposure.
Conclusion: This study provides the first data on bronchoalveolar lavage of healthy South African children. Bronchoalveolar
lavage fluid from patients with pulmonary inflammation was characterised by neutrophilia. Finally, we propose
that exogenous surfactant treatment could help alleviate inflammation in diseased states where it occurs in
the tracheobronchial tree.
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Background
Bronchoalveolar lavage (BAL) is a procedure indicated
for children presenting with several inflammatory and
non-inflammatory lung conditions where a sample of
the endobronchial environment is taken. This allows for
the furthering knowledge regarding paediatric pneumo-
nopathies [1]. There are many restrictions regrading
BAL for research purposes, particularly for healthy to
normal BAL cellular and non-cellular constituents.
The aim of the present study was to 1) to assess the
cellular components in BALs of children with inflamma-
tory and non-respiratory problems, and 2) some of the
common inflammatory mediators and to establish
whether the synthetic pulmonary surfactant Synsurf®
elicits immunomodulatory and immunogenicity charac-
teristics in comparison to the natural derived surfactants,
Curosurf® and Liposurf®, currently used today. For this
purpose, we investigated cytokine production, of BAL
derived alveolar macrophages (AMs) treated with either
Synsurf®, Curosurf® or Liposurf®.
Methods
The study was performed under approval from the
Ethical Review Committee of the Faculty of Health
Sciences of Stellenbosch University (Reference N13/07/
099). After written informed consent, bronchoalveolar
sampling for this study were collected from children
deemed not to have infectious conditions (i.e. Tubercu-
losis or HIV). Samples where from children with struc-
tural problems that underwent bronchoscopy for
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diagnostic reasons. These were healthy children with
upper airway obstruction or chronic stridor without evi-
dence of parenchymal disease on their X-rays or acute
infection. Bronchoscopy was only done in these children
when they were healthy and had no respiratory symp-
toms during the two weeks before the bronchoscope
procedure. BAL sample collection was performed after
topical anaesthesia with 4010 lidocaine spray. A flexible
fibre optic bronchoscope was introduced through the
upper airway and wedged in a segment of the right mid-
dle lobe. One 4–8 ml of BAL aliquot per patient was as-
pirated with gentle hand suction and collected for this
study. A total of 30 paediatric patients’ BAL samples
were collected.
Surfactant preparations
Synsurf® was prepared as described previously by van Zyl
et al. [2]. The natural surfactants used were Curosurf®, a
porcine lipid extract surfactant suspension (Chiesi
Farmaceutici SpA) and Liposurf®, a bovine lipid extract
surfactant suspension (Cipla).
Isolation of alveolar macrophages
AMs from bronchoalveolar lavage samples were isolated
from other contaminant cell types by Histopaque-1077
(Sigma, St. Louis, MO) density gradient centrifugation of
whole BAL aspirates. After isolation the cells were resus-
pended in RPMI 1640 (Roswell Park Memorial Institute
media) culture medium supplemented with 10% fetal
calf serum, 1% l-glutamine solution (200 mM), and 1%
Penicillin-Streptomycin. After cell counting, AMs sam-
ples were allowed to adhere in 6 well flat bottom cell
culture plates maintained in a humidified 5% CO2–95%
atmospheric air incubator at 37 °C. To ensure macro-
phage survival and adherence, the cells were supple-
mented with up to 25% fetal calf serum in the beginning.
This was usually refreshed only once thereafter at the
same concentration followed by 10% supplementation as
indicated above. Cells were left overnight to attach to
the culture plates. All nonadherent cells that floated
were regarded as “non-viable” and were “washed” off.
Only adhered macrophages were considered as alive
(used in the experiments after ~ 12 h). This procedure
possibly also helped to separate lymphocytes from the
population. Cell viability was assessed by trypan blue ex-
clusion before conducting each experiment. Equal parts
of 0.4% trypan blue dye was added to the cell suspension
to obtain a 1 to 2 dilution before cell count. Live cells
with intact cell membranes are not coloured however, if
cells take up trypan blue, they are considered non-viable.
Viability was established at ~ 85–90%. Specific care was
taken upon harvesting of adherent cells to minimise in-
advertent activation.
Inflammatory cytokines
To evaluate the anti-inflammatory effects of exogenous
surfactants, Curosurf®, Liposurf® and Synsurf® were stan-
dardised to equivalent phospholipid concentrations,
500–1500 μg/ml and incubated with LPS- (1 μg/ml)
stimulated BAL-derived AMs over 24 h. Control samples
consisted of LPS-stimulated AMs samples devoid of any
surfactant. Cytokines production in the alveolar macro-
phage supernatants were analysed by using a multiplex
(V-PLEX) human cytokines’ electrochemiluminescence-
based ELISA kit (Meso Scale Discovery®) as per manu-
facturer’s instructions. All samples were run in duplicate,
and the mean values were used for statistical analysis.
Values were calculated in picogram cytokine per
milliliter (pg/ml) of sample. Cytokines screened for were:
IL-1β, IL-2, TNF-α, IL-6, IL-8, INF-γ, GM-CSF, IL-10,
IL-12.
Results
As shown in Fig. 1, the representative haematoxylin and
eosin (H&E) staining indicate different cell populations
found in BAL samples. Figure 1a and b demonstrated a
larger population of neutrophils indicating neutrophilia.
These populations were excluded from the current study
as our focus was on macrophage initiated cytokine re-
lease. Figure 1c and d indicates the optimal cell popula-
tion that was used as a standard for the appropriation of
the study.
During our experiments to assess the release of cyto-
kines by LPS-stimulated AMs as well as in the presence
of surfactants, we were mindful that during the enrich-
ment and handling processes of these cells, disturbance
of the original milieu as well as even the transfer process
to cell culture plates could be modulatory on cytokine
production. Table 1 represent the results of stimulated
macrophage secretion of the nine inflammatory cyto-
kines we studied. Comparison of the different surfac-
tants with regards to inflammatory and anti-
inflammatory cytokine secretion did not reveal signifi-
cant differences; therefore, data representation is more
effective within descriptive statistical analysis.
Comparing the analyses of cytokine production during
LPS stimulation of AMs, revealed the following overall
concentrations as depicted in Table 1: IL-1β (0.25–200
pg/106 cells); IL-2 (0.1–7 pg/ml) and IFN-γ (5 pg/ml).
An increase in the amount of GM-CSF (100 pg/ml),
TNF-α and IL-6 (400–600 pg/106 cells) were found.
Moreover, IL-8 was secreted in the nanogram range (3.5
ng/106 cells). Compared to control levels, the pro-
inflammatory cytokine secretion was decreased in all
three surfactant groups after 24 h exposure. On the
other hand, anti-inflammatory cytokines, IL-10 and IL-
12, were also seen to be secreted at low levels under
LPS-stimulated conditions, but exhibited the opposite
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nature to the pro-inflammatory cytokines by increasing
in secretion when exposed to surfactants.
Discussion
The use in pulmonary surfactant replacement therapy as
a standard care for premature infants with respiratory
distress syndrome is well established. However, in
addition to its function to modulate surface tension at
the air-liquid interface, pulmonary surfactant also have
immune modulatory properties. Regrettably, the exact
mechanisms by which exogenous surfactants modulate
the inflammatory cascade in AMs are still unclear, thus
making it important to study the complex interplay
among the inflammatory cytokines (inducer or suppres-
sor effects of one cytokine against another) in order to
eventually unravel its involvement in inflammatory pul-
monary conditions. This prompted us to compare the
potential immune modulatory effects of the synthetic
pulmonary surfactant Synsurf® on AMs with that of the
natural extracted surfactants Curosurf® and Liposurf®.
Due to the small sample size of healthy patients, a
standardised cell culture concentration was maintained
as to keep statistical integrity regarding pool size. Under
our in vitro experimental conditions, mindful consider-
ation was given during the fractionation [3] and hand-
ling processes of AMs when we interpreted our results.
This was necessary as other researchers showed that
macrophage adherence in itself to cell culture dishes, re-
sults in the production and release of certain inflamma-
tory mediators [4, 5].
We found a low relationship between LPS stimulated
release of IL-1β, IL-2, IL-6 and IL-8 and their spontan-
eous secretion during prolonged exposure to LPS in
combination with surfactant. Synsurf® displayed an ap-
proximate two-fold decrease in IL-1β release (97.60 pg/
ml) compared to control levels (176.45 pg/ml) whereas
both natural surfactants displayed minimal decreases.
After 24 h, TNF-α levels decreased within the cell super-
natant of the surfactant treated AMs. The Curosurf®
(120.73 pg/ml) and Liposurf® (110.01 pg/ml) groups dis-
played an approximate four-fold decrease in TNF-α re-
lease compared to control levels (462 pg/ml); whereas,
Synsurf® (56.87 pg/ml) displayed a much larger, eight-
fold, inhibitory effect on stimulated TNF-α release.
TNF-α and IL-1β release by macrophages are “acute re-
sponse” cytokines that promote neutrophilic and eosino-
philic inflammation. Although they are not directly
chemo-attractive agents, they may directly or indirectly
stimulate the upregulation of relevant secondary cyto-
kines and cell adhesion molecules. The increased pres-
ence of TNF-α and IL-1β may synergistically amplify the
expression of IL-6 and IL-8 [6]. This being said, it has
Fig. 1 H&E staining of human BAL sample after mononuclear cell isolation from patient diagnosed with asthma (a & b) and a healthy patient
with an airway obstruction (c & d); Abbreviations: M: Macrophage, N: Neutrophil, Eos: Eosinophil, MD: Mucus debris. Scale bar represents: (a & b)
50 μm, (c) 100 μm, (d) 500 px
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been seen that peak TNF-α and IL-1β AM release occurs
between approximately 8–12 h after initial exposure [7].
This may explain the rather low LPS stimulated levels of
these cytokines at 24 h compared to that of their
downstream-regulated cytokines IL-6 and IL-8 (although
both IL-6 and IL-8 are decreased within all three the
surfactant groups) which may reach their peak concen-
trations much later. IL-6 was also found to be at much
lower levels compared to IL-8. A previous study showed
a similar phenomenon and elucidated the relationship
between basal secretion and initial spontaneous release
for IL-8, IL-6 and TNF- α in culture; once again
highlighting the significant cell adherence effect and its
subsequent stimulus on cytokine secretion [5].
Both natural pulmonary surfactants decreased
secretory levels of IL-2 whereas cell supernatant levels of
IL-2 where increased when exposed to the synthetic pul-
monary surfactant Synsurf®. It is important to note that
IL-2 activates several different pathways that mediate the
flow of mitogenic and survival-promoting signals [8].
Moreover, IL-2 induces the JAB/suppressor of cytokine
signalling 1 (JAB/SOCS1/SSI-1) that in turn inhibits IL-
2 signalling [9]. SOCS1 is involved in the negative
regulation of cytokines and initiates an anti-
inflammatory response via the regulation of homeostasis.
Thus indicating that IL-2 also has anti-inflammatory
properties, as does other pro-inflammatory cytokines,
such as IFN-γ [10]. Levels of IFN-γ secretion decreased
almost 3-fold when AMs were exposed to Curosurf® and
Synsurf®; however, only an approximate 2-fold decrease
Table 1 The mean, SD (standard deviation), P25 (25th
percentile), P50 (median), & P75 (75th percentile) of LPS (1 μg/
ml)-stimulated cytokine production in BAL-derived human
alveolar macrophage supernatant concentrations measured at
24 h in the presence of surfactants. Control samples - LPS –
stimulated AMs
Control Curosurf® Liposurf® Synsurf®
IL-1β (pg/ml)
Mean 176.45 168.87 118.01 97.6
SD 305.32 292.62 210.07 166.01
P25 0.09 0.3 0.34 0.27
P50 0.25 0.39 1.29 0.6
P75 529 495.5 300.5 332
IL2 (pg/ml)
Mean 7.61 5.16 4.38 10.91
SD 1126 7.77 5.84 19.03
P25 0.017 0.14 0.22 0.14
P50 0.0722 0.38 0.022 0.31
P75 1951 7.25 8.86 27.45
IL6 (pg/ml)
Mean 650.4 452.78 321.08 265.7
SD 1126 815.29 634.03 412.02
P25 0.017 0.17 0.07 0.14
P50 0.0722 0.29 0.18 0.24
P75 1951 1134 341 759.5
IL8 (pg/ml)
Mean 3588 3193.71 3139.73 3101.79
SD 6020 5153.64 5081.01 4997.25
P25 55.35 89 84.5 95.75
P50 169 249.5 251 198.5
P75 10,540 10,532.5 10,316.5 10,273
TNF-α (pg/ml)
Mean 462 120.73 110.01 56.87
SD – 195.09 181.01 99.96
P25 – 0.08 0.1 0.08
P50 – 0.13 30.98 0.13
P75 – 273.5 219.93 95.35
INF-γ (pg/ml)
Mean 5.771 1.93 3.06 1.12
SD 8.039 2.5 4.8 0.85
P25 0.0864 0.28 0.45 0.55
P50 5.771 0.49 0.82 0.6
P75 11.46 2.57 5.68 1.75
GM-CSF (pg/ml)
Mean 114.1 84.5 61.89 62.33
SD 197.3 157.67 129.1 107.94
P25 0.1176 0.28 0.21 0.06
Table 1 The mean, SD (standard deviation), P25 (25th
percentile), P50 (median), & P75 (75th percentile) of LPS (1 μg/
ml)-stimulated cytokine production in BAL-derived human
alveolar macrophage supernatant concentrations measured at
24 h in the presence of surfactants. Control samples - LPS –
stimulated AMs (Continued)
Control Curosurf® Liposurf® Synsurf®
P50 0.2565 0.35 0.42 0.22
P75 342 183 86.3 184
IL10 (pg/ml)
Mean 0.186 18.05 15.58 4.88
SD – 29.7 29.76 8.36
P25 – 0.1244 0.11435 0.157
P50 – 0.176 1.012 0.1635
P75 – 21.25 31.0475 4.55
IL12 (pg/ml)
Mean 2.93 20.1 15.39 16.14
SD 3.966 39.377 18.07 22.08
P25 0.1259 0.24 0.21 0.34
P50 2.93 0.56 12.74 0.35
P75 5.735 39.95 30.58 33.7
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in the presence of Liposurf® was witnessed. IFN-γ is im-
portant for the clearance of bacteria by recruiting many
other cells (e.g. NK cells), but some reports indicate that
IFN-γ is crucial for the cell cycle arrest in macrophage
cell cycles that provides a survival signal, and others sug-
gest that it serves as a pro-apoptotic signal. There have
been many advances in the understanding of cell cycle
control and apoptosis within isolation; however, the
inter-relationship between these intimately related pro-
cesses concerning protective immunity and immunopa-
thology are yet to be fully understood [11].
Conclusion
There are few studies found in literature on BALs in
healthy children as the procedure ethically refers to re-
spiratory problems. This study approached the problem
by collecting samples from healthy paediatric patients
undergoing fiberoptic bronchoscopy for various reasons
without evidence of respiratory tract infections similar
to that of previous studies. Our study provides the first
data on healthy BALs among South African children
without inflammatory pulmonary conditions and the
subsequent effect of exogenous surfactant on BAL in-
flammatory cellular components.
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